YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Antiviral Research

• Publication date

  2005-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.ANTIVIRAL.2004.12.002PMID 15708639
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus.

  2004cited by this paper
• Orally Active Fusion Inhibitor of Respiratory Syncytial Virus

  2004cited by this paper
• Mortality associated with influenza and respiratory syncytial virus in the United States.

  2003cited by this paper
• Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus.

  2003cited by this paper
• Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein

  2003cited by this paper
• RFI-641, a Potent Respiratory Syncytial Virus Inhibitor

  2002cited by this paper
• DIAGNOSIS OF LEGIONELLA INFECTION

  2002cited by this paper
• RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein.

  2001cited by this paper
• Impact of respiratory virus infections on persons with chronic underlying conditions.

  2000cited by this paper
• Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo.

  2000cited by this paper
• Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon

  2000cited by this paper
• The Cys3-His1 Motif of the Respiratory Syncytial Virus M2-1 Protein Is Essential for Protein Function

  2000cited by this paper
• Inhibition of respiratory syncytial virus by a new class of chemotherapeutic agents

  2000cited by this paper
• The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription.

  1999cited by this paper
• The Major Attenuating Mutations of the Respiratory Syncytial Virus Vaccine Candidate cpts530/1009 Specify Temperature-Sensitive Defects in Transcription and Replication and a Non-Temperature-Sensitive Alteration in mRNA Termination

  1999cited by this paper
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  1998cited by this paper
• CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats.

  1998cited by this paper
• Respiratory syncytial virus (RSV) disease and prospects for its control.

  1998cited by this paper
• Respiratory Viral Infections in Immunocompetent and Immunocompromised Persons

  1997cited by this paper
• Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection.

  1996cited by this paper
• Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions

  1996cited by this paper
• Respiratory syncytial virus and influenza A infections in the hospitalized elderly.

  1995cited by this paper
• Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls.

  1995cited by this paper
• Mandell, Douglas and Bennett's principles and practice of infectious diseases. Volumes 1 and 2. Fourth edition.

  1995cited by this paper
• RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA

  1995cited by this paper
• Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication

  1995cited by this paper
• Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.

  1995cited by this paper
• A sensitive assay system screening antiviral compounds against herpes simplex virus type 1 and type 2.

  1994cited by this paper
• MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents.

  1994cited by this paper
• Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice.

  1993cited by this paper
• Respiratory syncytial virus or influenza?

  1993cited by this paper
• Effects of protease inhibitors on replication of various myxoviruses

  1992cited by this paper
• An epidemic of respiratory syncytial virus in elderly people: Clinical and serological findings

  1990cited by this paper
• Biochemistry and clinical applications of ribavirin

  1986cited by this paper
• Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease.

  1986cited by this paper
• Ribavirin Treatment of Respiratory Syncytial Viral Infection in Infants With Underlying Cardiopulmonary Disease

  1985cited by this paper
• Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

  1983cited by this paper
• RESPIRATORY SYNCYTIAL VIRUS

  1982cited by this paper
• Effects of ribavirin on respiratory syncytial virus in vitro

  1980cited by this paper

• Recent advances of the respiratory syncytial virus inhibitors.

  2025cites this paper
• Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic Profile.

  2025cites this paper
• Exploring the secrets of virus entry: the first respiratory syncytial virus carrying beta lactamase

  2024cites this paper
• JNJ-7184, a Respiratory Syncytial Virus inhibitor targeting the connector domain of the viral polymerase.

  2024cites this paper
• Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents.

  2024cites this paper
• Structural basis of paramyxo- and pneumovirus polymerase inhibition by non-nucleoside small-molecule antivirals

  2024cites this paper
• Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerases

  2023cites this paper
• Current state and challenges in respiratory syncytial virus drug discovery and development.

  2023cites this paper
• Structural and mechanistic insights into the inhibition of respiratory syncytial virus polymerase by a non-nucleoside inhibitor

  2023cites this paper
• Licochalcone A plays dual antiviral roles by inhibiting RSV and protecting against host damage

  2023cites this paper
• Insight into non-nucleoside triazole-based systems as viral polymerases inhibitors.

  2023cites this paper
• Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase

  2022influential citation
• Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor

  2021cites this paper
• Uracil derivatives as non-nucleoside inhibitors of viral infections

  2021cites this paper
• Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses.

  2021cites this paper
• Screening and pharmacodynamic evaluation of the anti‐respiratory syncytial virus activity of butene lactones in vitro and in vivo

  2020cites this paper
• A protocol of systematic review and meta-analysis

  2020cites this paper
• Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis.

  2020cites this paper
• Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity

  2020cites this paper
• High-throughput screening of active compounds against human respiratory syncytial virus.

  2019cites this paper
• Quercetin pentaacetate inhibits in Vitro Human Respiratory Syncytial Virus adhesion.

  2019cites this paper
• Late therapeutic intervention with a respiratory syncytial virus L‐protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium

  2018cites this paper
• State of the Art in Respiratory Syncytial Virus Drug Discovery and Development.

  2018cites this paper
• Développement de vaccins sous-unitaires contre le métapneumovirus humain

  2018cites this paper
• Antiviral Drugs for Acute Infections

  2017cites this paper
• Respiratory syncytial virus: prospects for new and emerging therapeutics

  2017cites this paper
• Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor

  2017influential citation
• Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus

  2017cites this paper
• Discovery of novel benzothienoazepine derivatives as potent inhibitors of respiratory syncytial virus.

  2017cites this paper
• Development of a novel cell-based screening platform to identify inhibitors of viral interferon antagonists from clinically important viruses

  2016influential citation
• Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.

  2016cites this paper
• New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase.

  2016cites this paper
• Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase

  2016cites this paper
• Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection.

  2015cites this paper
• Title : Antiviral efficacy of an RSV fusion inhibitor in a bovine model of RSV infection

  2015cites this paper
• High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors

  2015cites this paper
• Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen.

  2015cites this paper
• The Interferon Type I/III Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells Can Be Attenuated or Amplified by Antiviral Treatment

  2015cites this paper
• GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process

  2015cites this paper
• Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter

  2015cites this paper
• Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection

  2015cites this paper
• A Phenotypic High-Throughput Screen with RSV-Infected Primary Human Small Airway Epithelial Cells (SAECs)

  2015cites this paper
• Quantitative investigation of the affinity of human respiratory syncytial virus phosphoprotein C-terminus binding to nucleocapsid protein

  2014cites this paper
• Characterization of a Respiratory Syncytial Virus L Protein Inhibitor

  2014cites this paper
• Optimization of Potent and Selective Quinazolinediones: Inhibitors of Respiratory Syncytial Virus That Block RNA-Dependent RNA-Polymerase Complex Activity

  2014cites this paper
• Development of a high-throughput replicon assay for the identification of respiratory syncytial virus inhibitors.

  2014cites this paper
• Understanding respiratory syncytial virus infection to improve treatment and immunity.

  2013cites this paper
• Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor.

  2013cites this paper
• Comparing Influenza and Rsv Viral and Disease Dynamics in Experimentally Infected Adults Predicts Clinical Effectiveness of Rsv Antivirals

  2013cites this paper
• A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus

  2013cites this paper
• Respiratory syncytial virus disease: prevention and treatment.

  2013cites this paper
• Complementary approaches to target human respiratory syncytial virus using small molecule ligands

  2012cites this paper
• Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion: A Focus on Respiratory Syncytial Virus

  2012cites this paper
• (S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.

  2012cites this paper
• The Prophylaxis and Treatment with Antiviral Agents of Respiratory Syncytial Virus Infections

  2012cites this paper
• Treatment of Respiratory Syncytial Virus Infection : Past , Present and Future

  2012cites this paper
• The viral RNA capping machinery as a target for antiviral drugs

  2012cites this paper
• Inhibition activities of polysaccharide (RG4-1) from Gentiana rigescens against RSV

  2011cites this paper
• Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

  2011cites this paper
• RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses.

  2011cites this paper
• Honey as an antiviral agent against respiratory syncytial virus

  2011cites this paper
• Matériels et méthodes de traitement d'états associés à biofilm pathogène

  2011cites this paper
• Discovery and Development of RSV604

  2011cites this paper
• Treatment of Respiratory Syncytial Virus Infection: Past, Present and Future

  2011cites this paper
• Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

  2010cites this paper
• An investigation into the chemical nature and mechanism of action of antiviral compounds of natural origin.

  2010cites this paper
• Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

  2010cites this paper
• The Infectious March: The Complex Interaction Between Microbes and the Immune System in Asthma

  2010cites this paper
• Two novel fusion inhibitors of human respiratory syncytial virus.

  2010cites this paper
• Augmenting antiviral host defense in the respiratory epithelium

  2009cites this paper
• Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo

  2007influential citation
• Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses

  2007cites this paper
• Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)

  2007cites this paper
• Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus

  2007cites this paper
• Respiratory syncytial virus infections: recent prospects for control.

  2006cites this paper
• Development of Antivirals against Respiratory Syncytial Virus

  2006cites this paper
• Respiratory Syncytial Virus Infection in Adults

  2005influential citation
• Inhibitors of Respiratory Syncytial Virus Replication Target Cotranscriptional mRNA Guanylylation by Viral RNA-Dependent RNA Polymerase

  2005cites this paper